grant

The role Survivin and XIAP (X-linked inhibitor of apoptosis protein) as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia. [ 2012 - 2016 ]

Also known as: A study to assess the mechanisms of cell death in acute myeloid leukaemia.

Funded by National Health and Medical Research Council
Managed by The University of Queensland
Managed by University of Queensland
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1036907]

Researchers: Dr Andrew Moore (Principal investigator)

Brief description I am a Paediatric Haematologist/Oncologist focussing on new treatments for childhood acute myeloid leukaemia. This study is examining the effects of conventional and novel therapies on two proteins that prevent cell death in acute myeloid leukaemia. The study will also develop clinical trials of new drugs targeting these proteins.

Funding Amount $AUD 294,218.53

Funding Scheme Early Career Fellowships

Notes Health Professional Research ECF

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Medical and Health Sciences | Molecular Targets | Oncology and Carcinogenesis | acute myeloid leukaemia (AML) | cancer biology | cancer chemotherapeutic agents | molecular oncology | paediatric |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA